Appropriate Chemotherapy Dosing for Obese Adult Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline
Open accessThe DOI matches its Crossref record; 101 of the 101 references it cites were found in a registry or an index.
Abstract
Purpose: To provide recommendations for appropriate cytotoxic chemotherapy dosing for obese adult patients with cancer. Methods: The American Society of Clinical Oncology convened a Panel of experts in medical and gynecologic oncology, clinical pharmacology, pharmacokinetics and pharmacogenetics, and biostatistics and a patient representative. MEDLINE searches identified studies published in English between 1996 and 2010, and a systematic review of the literature was conducted. A majority of studies involved breast, ovarian, colon, and lung cancers. This guideline does not address dosing for novel targeted agents. Results: Practice pattern studies demonstrate that up to 40% of obese patients receive limited chemotherapy doses that are not based on actual body weight. Concerns about toxicity or overdosing in obese patients with cancer, based on the use of actual body weight, are unfounded. Recommendations: The Panel recommends that full weight–based cytotoxic chemotherapy doses be used to treat obese patients with cancer, particularly when the goal of treatment is cure. There is no evidence that short- or long-term toxicity is increased among obese patients receiving full weight–based doses. Most data indicate that myelosuppression is the same or less pronounced among the obese than the non-obese who are administered full weight–based doses. Clinicians should respond to all treatment-related toxicities in obese patients in the same ways they do for non-obese patients. The use of fixed-dose chemotherapy is rarely justified, but the Panel does recommend fixed dosing for a few select agents. The Panel recommends further research into the role of pharmacokinetics and pharmacogenetics to guide appropriate dosing of obese patients with cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. Adults
Calle, E. E., Rodriguez, C., Walker-Thurmond, K., & Thun, M. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021423 · Cited by 7,696 · cited 1×
“Many cancers are more common in obese people, and cancer-specific outcomes tend to be worse among the obese.(27) Poorer outcomes among obese patients are most likely multifactorial.”
BackgroundUnequal treatment: confronting racial and ethnic disparities in health care
(2003) · Choice Reviews Online · doi:10.5860/choice.40-5843 · Cited by 7,043
Coiffier, B., Lepage, E., Brière, J., Herbrecht, R., Tilly, H., Bouabdallah, R., Morel, P., Van Den Neste, E., Salles, G., Gaulard, P., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011795 · Cited by 5,574
Simplified calculation of body surface area
(1987) · New England Journal of Medicine · doi:10.1056/nejm198710223171717 · Cited by 3,238
Wang, Y., & Beydoun, M. A. (2007) · Epidemiologic Reviews · doi:10.1093/epirev/mxm007 · Cited by 2,792
Health and economic burden of the projected obesity trends in the USA and the UK
Wang, Y. C., McPherson, K., Marsh, T., Gortmaker, S. L., & Brown, M. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60814-3 · Cited by 2,692
Pfreundschuh, M., Trümper, L., Österborg, A., Pettengell, R., Trneny, M., Imrie, K., Ma, D., Gill, D., Walewski, J., Zinzani, P.-L., et al. (2006) · The Lancet Oncology · doi:10.1016/s1470-2045(06)70664-7 · Cited by 2,076
Carboplatin dosage: prospective evaluation of a simple formula based on renal function.
Calvert, A. H., Newell, D. R., Gumbrell, L. A., O'Reilly, S., Burnell, M., Boxall, F. E., Siddik, Z. H., Judson, I. R., Gore, M. E., & Wiltshaw, E. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.11.1748 · Cited by 1,866
Cancer Disparities by Race/Ethnicity and Socioeconomic Status
Ward, E., Jemal, A., Cokkinides, V., Singh, G. K., Cardinez, C., Ghafoor, A., & Thun, M. (2004) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.54.2.78 · Cited by 1,801
Freireich, E. J., Gehan, E. A., Rall, D. P., Schmidt, L. H., & Skipper, H. E. (1966) · PubMed · Cited by 1,382
Bonadonna, G., Valagussa, P., Moliterni, A., Zambetti, M., & Brambilla, C. (1995) · New England Journal of Medicine · doi:10.1056/nejm199504063321401 · Cited by 1,049
The importance of dose intensity in chemotherapy of metastatic breast cancer.
Hryniuk, W., & Bush, H. (1984) · Journal of Clinical Oncology · doi:10.1200/jco.1984.2.11.1281 · Cited by 885
Self-citationDose: A critical factor in cancer chemotherapy
Frei, E., & Canellos, G. P. (1980) · The American Journal of Medicine · doi:10.1016/0002-9343(80)90472-6 · Cited by 839
Dose-Response Effect of Adjuvant Chemotherapy in Breast Cancer
Bonadonna, G., & Valagussa, P. (1981) · New England Journal of Medicine · doi:10.1056/nejm198101013040103 · Cited by 774
Effect of Obesity on the Pharmacokinetics of Drugs in Humans
Hanley, M. J., Abernethy, D. R., & Greenblatt, D. J. (2010) · Clinical Pharmacokinetics · doi:10.2165/11318100-000000000-00000 · Cited by 773
Body Composition as an Independent Determinant of 5-Fluorouracil–Based Chemotherapy Toxicity
Prado, C. M. M., Baracos, V. E., McCargar, L. J., Mourtzakis, M., Mulder, K. E., Reiman, T., Butts, C. A., Scarfe, A. G., & Sawyer, M. B. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-3067 · Cited by 619
Dose and Dose Intensity as Determinants of Outcome in the Adjuvant Treatment of Breast Cancer
Budman, D. R., Berry, D. A., Cirrincione, C. T., Henderson, Wood, W. C., Weiss, R. B., Ferree, C. R., Muss, H. B., Green, M. R., Norton, L., et al. (1998) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/90.16.1205 · Cited by 577
Race/Ethnic Issues in Obesity and Obesity-Related Comorbidities
Cossrow, N., & Falkner, B. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0339 · Cited by 472
Lyman, G. H., Dale, D. C., & Crawford, J. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.05.002 · Cited by 464
Self-citationAnalysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer.
Hryniuk, W., & Levine, M. N. (1986) · Journal of Clinical Oncology · doi:10.1200/jco.1986.4.8.1162 · Cited by 456
Self-citationKwak, L. W., Halpern, J., Olshen, R. A., & Horning, S. J. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.6.963 · Cited by 431
Adjuvant Chemotherapy in Older and Younger Women With Lymph Node–Positive Breast Cancer
Muss, H. B. (2005) · JAMA · doi:10.1001/jama.293.9.1073 · Cited by 418
Curing metastatic testicular cancer
Einhorn, L. H. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.072067999 · Cited by 387
Impact of Chemotherapy Dose Intensity on Cancer Patient Outcomes
Lyman, G. H. (2009) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2009.0009 · Cited by 383
Self-citationGurney, H. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.9.2590 · Cited by 361
What is the best size descriptor to use for pharmacokinetic studies in the obese?
Green, B., & Duffull, S. B. (2004) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2004.02157.x · Cited by 353
Muss, H. B., Berry, D. A., Cirrincione, C., Budman, D. R., Henderson, I. C., Citron, M. L., Norton, L., Winer, E. P., & Hudis, C. A. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.10.9710 · Cited by 339
Obesity and the economics of prevention: fit not fat
(2011) · Choice Reviews Online · doi:10.5860/choice.48-6419 · Cited by 329
Lyman, G. H., Dale, D. C., Friedberg, J., Crawford, J., & Fisher, R. I. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.03.213 · Cited by 315
Self-citationMeyerhardt, J. A., Catalano, P. J., Haller, D. G., Mayer, R. J., Benson, A. B., Macdonald, J. S., & Fuchs, C. S. (2003) · Cancer · doi:10.1002/cncr.11544 · Cited by 306
Fuchs, C. S., Moore, M. R., Harker, G., Villa, L., Rinaldi, D., & Hecht, J. R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.08.058 · Cited by 296
Undertreatment of Obese Women Receiving Breast Cancer Chemotherapy
Griggs, J. J., Sorbero, M. E. S., & Lyman, G. H. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.11.1267 · Cited by 289
Self-citationRole of Body Surface Area in Dosing of Investigational Anticancer Agents in Adults, 1991-2001
Baker, S. D., Verweij, J., Rowinsky, E. K., Donehower, R. C., Schellens, J. H. M., Grochow, L. B., & Sparreboom, A. (2002) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/94.24.1883 · Cited by 286
Self-citationBonneterre, J. M., Roche, H. H., Kerbrat, P., Bremond, A. G., Fumoleau, P., Namer, M., Goudier, M.-J., Schraub, S., Fargeot, P., & Chapelle-Marcillac, I. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.059 · Cited by 276
Meyerhardt, J. A., Tepper, J. E., Niedzwiecki, D., Hollis, D. R., McCollum, A. D., Brady, D., O'Connell, M. J., Mayer, R. J., Cummings, B., Willett, C., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.07.121 · Cited by 273
Meyerhardt, J. A., Niedzwiecki, D., Hollis, D., Saltz, L. B., Mayer, R. J., Nelson, H., Whittom, R., Hantel, A., Thomas, J., & Fuchs, C. S. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.6687 · Cited by 259
How to calculate the dose of chemotherapy
Gurney, H. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600139 · Cited by 251
Lichtman, S. M., Wildiers, H., Launay-Vacher, V., Steer, C., Chatelut, E., & Aapro, M. (2007) · European Journal of Cancer · doi:10.1016/j.ejca.2006.11.004 · Cited by 245
Dosing in Obesity: A Simple Solution to a Big Problem
Han, P. Y., Duffull, S. B., Kirkpatrick, C. M. J., & Green, B. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100381 · Cited by 241
The calculation of received dose intensity.
Hryniuk, W. M., & Goodyear, M. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.12.1935 · Cited by 233
Self-citationApplications of dose intensity to problems in chemotherapy of breast and colorectal cancer.
Hryniuk, W. M., Figueredo, A. T., & Goodyear, M. D. E. (1987) · PubMed · Cited by 227
Self-citation(2008) · Cited by 225
Body Surface Area as a Determinant of Pharmacokinetics and Drug Dosing
Sawyer, M., & Ratain, M. J. (2001) · Investigational New Drugs · doi:10.1023/a:1010639201787 · Cited by 223
Lichtman, S. M., Wildiers, H., Chatelut, E., Steer, C., Budman, D., Morrison, V. A., Tranchand, B., Shapira, I., & Aapro, M. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.10.6583 · Cited by 222
Self-citationDoxorubicin clearance in the obese.
Rodvold, K. A., Rushing, D. A., & Tewksbury, D. A. (1988) · Journal of Clinical Oncology · doi:10.1200/jco.1988.6.8.1321 · Cited by 213
Dosing strategies for anticancer drugs: the good, the bad and body-surface area
Felici, A., Verweij, J., & Sparreboom, A. (2002) · European Journal of Cancer · doi:10.1016/s0959-8049(02)00151-x · Cited by 206
Self-citationRacial Disparity in the Dose and Dose Intensity of Breast Cancer Adjuvant Chemotherapy
Griggs, J. J., Sorbero, M. E. S., Stark, A. T., Heininger, S. E., & Dick, A. W. (2003) · Breast Cancer Research and Treatment · doi:10.1023/a:1025481505537 · Cited by 185
Self-citationREACH 2010 Surveillance for Health Status in Minority Communities --- United States, 2001--2002.
Liao, Y., Tucker, P., Okoro, C. A., Giles, W. H., Mokdad, A. H., & Harris, V. B. (2004) · PubMed · doi:10.13016/aoif-dbw2 · Cited by 180
Emery, M. G., Fisher, J. M., Chien, J. Y., Kharasch, E. D., Dellinger, P. E., Kowdley, K. V., & Thummel, K. E. (2003) · Hepatology · doi:10.1053/jhep.2003.50342 · Cited by 179
Rosner, G. L., Hargis, J. B., Hollis, D. R., Budman, D. R., Weiss, R. B., Henderson, I. C., & Schilsky, R. L. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.11.3000 · Cited by 178
Self-citationThe calculation of actual or received dose intensity: a comparison of published methods.
Longo, D. L., Duffey, P. L., DeVita, V. T., Wesley, M. N., Hubbard, S. M., & Young, R. C. (1991) · Journal of Clinical Oncology · doi:10.1200/jco.1991.9.11.2042 · Cited by 177
Lepage, E., Gisselbrecht, C., Haioun, C., Sebban, C., Tilly, H., Bosly, A., Morel, P., Herbrecht, R., Reyes, F., & Coiffier, B. (1993) · Annals of Oncology · doi:10.1093/oxfordjournals.annonc.a058619 · Cited by 174
Friedenreich, C., Cust, A., Lahmann, P. H., Steindorf, K., Boutron-Ruault, M.-C., Clavel-Chapelon, F., Mesrine, S., Linseisen, J., Rohrmann, S., Boeing, H., et al. (2007) · Cancer Causes & Control · doi:10.1007/s10552-006-0113-8 · Cited by 173
Evaluation of Alternate Size Descriptors for Dose Calculation of Anticancer Drugs in the Obese
Sparreboom, A., Wolff, A. C., Mathijssen, R. H. J., Chatelut, E., Rowinsky, E. K., Verweij, J., & Baker, S. D. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.2938 · Cited by 168
Self-citationSocial and Racial Differences in Selection of Breast Cancer Adjuvant Chemotherapy Regimens
Griggs, J. J., Culakova, E., Sorbero, M. E. S., Poniewierski, M. S., Wolff, D. A., Crawford, J., Dale, D. C., & Lyman, G. H. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.2749 · Cited by 151
Self-citationDose intensity and hematologic toxicity in older cancer patients receiving systemic chemotherapy
Shayne, M., Culakova, E., Poniewierski, M. S., Wolff, D. A., Dale, D. C., Crawford, J., & Lyman, G. H. (2007) · Cancer · doi:10.1002/cncr.22939 · Cited by 145
Self-citationMathijssen, R. H. J., de Jong, F. A., Loos, W. J., van der Bol, J. M., Verweij, J., & Sparreboom, A. (2007) · The Oncologist · doi:10.1634/theoncologist.12-8-913 · Cited by 140
Self-citationGriggs, J. J., Culakova, E., Sorbero, M. E. S., van Ryn, M., Poniewierski, M. S., Wolff, D. A., Crawford, J., Dale, D. C., & Lyman, G. H. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.3063 · Cited by 135
Self-citationInfluence of obesity on drug disposition.
Blouin, R. A., Kolpek, J. H., & Mann, H. J. (1987) · PubMed · Cited by 130
Body-Surface Area–Based Dosing Does Not Increase Accuracy of Predicting Cisplatin Exposure
de Jongh, F. E., Verweij, J., Loos, W. J., de Wit, R., de Jonge, M. J. A., Planting, A. S. T., Nooter, K., Stoter, G., & Sparreboom, A. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.17.3733 · Cited by 130
Self-citationRelation between chemotherapy dose, oestrogen receptor expression, and body-mass index
Colleoni, M. A., Li, S., Gelber, R. D., Price, K. N., Coates, A. S., Castiglione‐Gertsch, M., & Goldhirsch, A. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67110-3 · Cited by 129
Factors Affecting Cytochrome P-450 3A Activity in Cancer Patients
Baker, S. D., van Schaik, R. H. N., Rivory, L. P., ten Tije, A. J., Dinh, K. L., Graveland, W. J., Schenk, P. W., Charles, K. A., Clarke, S. J., Carducci, M. A., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1371 · Cited by 125
Self-citationProspective Evaluation of the Pharmacokinetics and Toxicity Profile of Docetaxel in the Elderly
ten Tije, A. J., Verweij, J., Carducci, M. A., Graveland, W. J., Rogers, T., Pronk, T., Verbruggen, M. P., Dawkins, F. W., & Baker, S. D. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.082 · Cited by 114
Impact of Body-Size Measures on Irinotecan Clearance: Alternative Dosing Recommendations
Mathijssen, R. H. J., Verweij, J., de Jonge, M. J. A., Nooter, K., Stoter, G., & Sparreboom, A. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.1.81 · Cited by 113
Self-citationThe Impact of Obesity and Disease on Busulfan Oral Clearance in Adults
Gibbs, J. P., Gooley, T. A., Corneau, B., Murray, G., STEWART, P. S., Appelbaum, F. R., & Slattery, J. T. (1999) · Blood · doi:10.1182/blood.v93.12.4436 · Cited by 111
Racial and Ethnic Disparities in Care: The Perspectives of Cardiologists
Lurie, N., Fremont, A., Jain, A. K., Taylor, S. L., McLaughlin, R., Peterson, E., Kong, B. W., & Ferguson, T. B. (2005) · Circulation · doi:10.1161/01.cir.0000157738.12783.71 · Cited by 109
Dosing chemotherapy in obese patients: Actual versus assigned body surface area (BSA)
Hunter, R. J., Navo, M. A., Thaker, P. H., Bodurka, D. C., Wolf, J. K., & Smith, J. A. (2008) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2008.07.005 · Cited by 107
Lichtman, S. M., Hollis, D. R., Miller, A. A., Rosner, G. L., Rhoades, C. A., Lester, E. P., Millard, F. E., Byrd, J. C., Cullinan, S. A., Rosen, D. M., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.9289 · Cited by 97
Self-citationField, K. M., Kosmider, S., Jefford, M., Michael, M., Jennens, R. R., Green, M., & Gibbs, P. (2008) · Journal of Oncology Practice · doi:10.1200/jop.0832001 · Cited by 97
Commentary: Oncologic Drugs in Patients with Organ Dysfunction: A Summary
Superfin, D., Iannucci, A. A., & Davies, A. M. (2007) · The Oncologist · doi:10.1634/theoncologist.12-9-1070 · Cited by 93
Fontana, A., Galli, L., Fioravanti, A., Orlandi, P., Galli, C., Landi, L. M., Bursi, S., Allegrini, G., Fontana, E., Marsico, R. D., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-3317 · Cited by 88
Yamamoto, N., Tamura, T., Murakami, H., Shimoyama, T., Nokihara, H., Ueda, Y., Sekine, I., Kunitoh, H., Ohe, Y., Kodama, T., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.11.036 · Cited by 86
Smorenburg, C. H., Sparreboom, A., Bontenbal, M., Stoter, G., Nooter, K., & Verweij, J. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.01.058 · Cited by 74
Self-citationAltered clearance of unbound paclitaxel in elderly patients with metastatic breast cancer
Smorenburg, C. H., ten Tije, A. J., Verweij, J., Bontenbal, M., Mross, K. B., van Zomeren, D. M., Seynaeve, C., & Sparreboom, A. (2002) · European Journal of Cancer · doi:10.1016/s0959-8049(02)00611-1 · Cited by 70
Self-citationThe Importance of Planned Dose of Chemotherapy on Time: Do We Need to Change Our Clinical Practice?
Foote, M. (1998) · The Oncologist · doi:10.1634/theoncologist.3-5-365 · Cited by 70
Are medical oncologists biased in their treatment of the large woman with breast cancer?
Madarnas, Y., Sawka, C. A., Franssen, E., & Bjarnason, G. A. (2001) · Breast Cancer Research and Treatment · doi:10.1023/a:1010635328299 · Cited by 65
Poikonen, C. B. P. (2001) · Acta Oncologica · doi:10.1080/028418601750071082 · Cited by 65
Carboplatin dosing in obese women with ovarian cancer: A Gynecologic Oncology Group study
Wright, J. D., Tian, C., Mutch, D. G., Herzog, T. J., Nagao, S., Fujiwara, K., & Powell, M. A. (2008) · Gynecologic Oncology · doi:10.1016/j.ygyno.2008.02.023 · Cited by 64
Modesitt, S. C., Tian, C., Kryscio, R. J., Thigpen, J. T., Randall, M. E., Gallion, H. H., & Fleming, G. F. (2006) · Gynecologic Oncology · doi:10.1016/j.ygyno.2006.10.045 · Cited by 64
Carboplatin dosing in overweight and obese patients with normal renal function, does weight matter?
Ekhart, C., Rodenhuis, S., Schellens, J. H. M., Beijnen, J. H., & Huitema, A. D. R. (2008) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-008-0856-x · Cited by 63
Chemotherapy dose intensity and quality cancer care.
Lyman, G. H. (2006) · PubMed · Cited by 61
Self-citationBénézet, S., Guimbaud, R., Chatelut, É., Chevreau, C., Bugat, R., & Canal, P. (1997) · Annals of Oncology · doi:10.1023/a:1008259009500 · Cited by 57
Wasil, T., & Lichtman, S. M. (2005) · The Oncologist · doi:10.1634/theoncologist.10-8-602 · Cited by 55
Flat-Fixed Dosing of Irinotecan
de Jong, F. A., Mathijssen, R. H. J., Xie, R., Verweij, J., & Sparreboom, A. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0591 · Cited by 52
Self-citationPharmacology of antineoplastic agents in older cancer patients
Lichtman, S. M., Skirvin, J. A., & Vemulapalli, S. (2003) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(02)00120-8 · Cited by 51
Smith, K. L., Wray, L., Klein-Cabral, M., Schuchter, L. M., Fox, K. R., Glick, J. H., & DeMichele, A. M. (2005) · Clinical Breast Cancer · doi:10.3816/cbc.2005.n.029 · Cited by 48
Greenman, C., Jagielski, C. H., & Griggs, J. J. (2008) · Cancer · doi:10.1002/cncr.23416 · Cited by 47
Self-citationObesity and Cancer Treatment: Weighing the Evidence
Griggs, J. J., & Sabel, M. S. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.4250 · Cited by 47
Self-citationPavlovsky, C., Egorin, M. J., Shah, D. D., Beumer, J. H., Rogel, S., & Pavlovsky, S. (2009) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.29.9.1152 · Cited by 42
Oral metronomic cyclophosphamide in elderly with metastatic melanoma
Borne, E., Desmedt, E., Duhamel, A., Mirabel, X., Dziwniel, V., Maire, C., Florin, V., Martinot, V. L., Penel, N., Vercambre-Darras, S., et al. (2009) · Investigational New Drugs · doi:10.1007/s10637-009-9298-5 · Cited by 38
Mastering chemotherapy dose reduction in elderly cancer patients
Wildiers, H. P. M. W. (2007) · European Journal of Cancer · doi:10.1016/j.ejca.2007.06.013 · Cited by 38
Lopes-Serrao, M. D., Ussery, S. M. G., Hall, R. G., & Shah, S. R. (2011) · Journal of Oncology Practice · doi:10.1200/jop.2010.000045 · Cited by 32
Loos, W. J., de Jongh, F. E., Sparreboom, A., de Wit, R., van Zomeren, D. M., Stoter, G., Nooter, K., & Verweij, J. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.0056 · Cited by 32
Self-citationCutaneous Angiosarcoma Complicating Morbid Obesity
Azam, M. A., Saboorian, M. H., Bieligk, S. C., Smith, T. P., & Molberg, K. H. (2001) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2001-125-0531-cacmo · Cited by 31
What is the effect of adjusting epirubicin doses for body surface area?
Dobbs, N. A., & Twelves, C. J. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.556 · Cited by 31
Grigg, A., Harun, M. H., & Szer, J. (1997) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428199709039036 · Cited by 20
Pharmacokinetics and pharmacodynamics in the elderly.
Lichtman, S. M. (2007) · PubMed · Cited by 16
Sparreboom, A., Loos, W. J., de Jonge, M. J. A., & Verweij, J. (2002) · Elsevier eBooks · doi:10.1016/b978-012072651-6/50019-x · Cited by 6
Self-citationCost effectiveness, chemotherapy, and the clinician
Griggs, J. J., & Sorbero, M. E. S. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-008-0142-y · Cited by 3
Self-citationSuccessful Transplant Outcome in a Morbidly Obese Patient with Acute Myeloblastic Leukemia
Ritchie, D. S., Wirth, A., & Grigg, A. (2001) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428190109097732 · Cited by 2
Cited by
Chan, D. S. M., Vieira, A. R., Aune, D., Bandera, E. V., Greenwood, D. C., McTiernan, A., Navarro Rosenblatt, D., Thune, I., Vieira, R., & Norat, T. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu042 · Cited by 1,165
Picon‐Ruiz, M., Morata‐Tarifa, C., Valle‐Goffin, J. J., Friedman, E. R., & Slingerland, J. M. (2017) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21405 · Cited by 893
NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 4.2016
Ettinger, D. S., Wood, D. E., Akerley, W., Bazhenova, L. A., Borghaei, H., Camidge, D. R., Cheney, R. T., Chirieac, L. R., D'Amico, T. A., Dilling, T. J., et al. (2016) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2016.0031 · Cited by 736
Obesity and Breast Cancer Prognosis: Evidence, Challenges, and Opportunities
Jiralerspong, S., & Goodwin, P. J. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.68.4480 · Cited by 405
Marra, M., Sammarco, R., De Lorenzo, A., Iellamo, F., Siervo, M., Pietrobelli, A., Donini, L. M., Santarpia, L., Cataldi, M., Pasanisi, F., et al. (2019) · Contrast Media & Molecular Imaging · doi:10.1155/2019/3548284 · Cited by 401
Metadata
- Authors
- Griggs, J. J., Mangu, P. B., Anderson, H., Balaban, E. P., Dignam, J. J., Hryniuk, W. M., Morrison, V. A., Pini, T. M., Runowicz, C. D., Rosner, G. L., Shayne, M., Sparreboom, A., Sucheston, L. E., & Lyman, G. H.
- Venue
- Journal of Clinical Oncology
- Published
- 2012-05-01
- Volume
- 30
- Issue
- 13
- Pages
- 1553-1561
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2148374907
- Cited by
- 485
- References
- 101
- FWCI
- 115.72
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.